China Cord Blood
The 10-second takeaway
For the quarter ended Dec. 31 (Q3), China Cord Blood met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly. GAAP earnings per share dropped.
Gross margins grew, operating margins expanded, net margins contracted.
China Cord Blood booked revenue of $19.4 million. The one analyst polled by S&P Capital IQ predicted revenue of $19.5 million on the same basis. GAAP reported sales were 59% higher than the prior-year quarter's $15.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.07. The one earnings estimate compiled by S&P Capital IQ forecast $0.05 per share. GAAP EPS of $0.07 for Q3 were 22% lower than the prior-year quarter's $0.09 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 81.1%, 400 basis points better than the prior-year quarter. Operating margin was 45.0%, much better than the prior-year quarter. Net margin was 22.5%, much worse than the prior-year quarter.
Next quarter's average estimate for revenue is $18.8 million. On the bottom line, the average EPS estimate is $0.04.
Next year's average estimate for revenue is $77.1 million. The average EPS estimate is $0.21.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 29 members out of 48 rating the stock outperform, and 19 members rating it underperform. Among 15 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), five give China Cord Blood a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on China Cord Blood is buy, with an average price target of $5.50.
Is China Cord Blood the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add China Cord Blood to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.